| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 29 | 72.6x | 17.8x | Bottom tier | |
Growth | 55 | 10.4% | 7.1% | Around median | |
Quality | 97 | 22.9% | 4.5% | Top tier | |
Safety | 56 | 2.3x | 2.6x | Around median | |
Capital Return | 51 | 2.66% | 2.12% | Around median | |
Momentum | 83 | 21.0% | 2.9% | Top tier | |
Sentiment | 84 | 19 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
AbbVie Inc. develops and markets medicines across four main areas: immunology, neuroscience, oncology, and aesthetics, with revenue generated by specific products including SKYRIZI, RINVOQ, HUMIRA, Vraylar, BOTOX, and VENCLEXTA. In Q2 fiscal year 2026, immunology was the largest contributor, with revenue of approximately $8.8 billion, followed by neuroscience with more than $3.2 billion, oncology with more than $1.6 billion, and aesthetics with approximately $1.3 billion.
Revenue in Q2 fiscal year 2026 was approximately $17.0 billion, representing reported operational growth of 10.2% and exceeding management expectations by approximately $300 million. Gross profit according to EDGAR filings was approximately $12.7 billion, or about 74.7% of revenue, while the company reported an adjusted gross margin of 84.7% and an adjusted operating margin of 48.3%. Net income reached $3.6 billion and GAAP earnings per share were $2.03, while adjusted earnings per share were $3.65, exceeding the midpoint of management guidance by $0.06.
SKYRIZI, RINVOQ, and neuroscience drove growth, with each delivering growth of more than 20% during Q2 fiscal year 2026. In contrast, oncology revenue declined operationally by 2.4% and aesthetics by 0.9%, while HUMIRA sales fell 36.1% due to biosimilars and IMBRUVICA sales fell 29.4% due to pricing and competition. This mix shows that growth from newer products is offsetting declines in some older products, but it increases reliance on sustained momentum from SKYRIZI, RINVOQ, and the neuroscience portfolio.
The analyst consensus is “Buy,” with an average price target of $285.92 and a wide range of $235 to $303; the average and highest target are above the top of the 52-week range of $267.47, while the lowest target is within the $190.75–$267.47 range. The data do not provide a valid price-to-earnings ratio for comparison, so the valuation assessment is based on fiscal year 2026 adjusted earnings per share guidance of between $13.87 and $14.07, balancing revenue growth against dilution from the Apogee transaction and declines in HUMIRA and IMBRUVICA. The $68 target spread reflects a fundamental difference in estimates of the ability of new products to offset the erosion of older products.
Figures in the text are as of 2026-08-25; the live price is shown at the top of the page.
Revenue was approximately $17.0 billion and grew 10.2%, exceeding management expectations by approximately $300 million. Performance was led by SKYRIZI, with sales of $5.5 billion and growth of 24%, and RINVOQ, with more than $2.5 billion and growth of 23.7%, alongside neuroscience growth of approximately 20%. Net income according to EDGAR was approximately $3.6 billion, while adjusted earnings per share were $3.65 and GAAP earnings per share were $2.03.
Combined sales of SKYRIZI and RINVOQ exceeded eight billion dollars in Q2 fiscal year 2026, compared with $706 million for HUMIRA. Sales of the two products grew operationally by 24% and 23.7%, respectively, while HUMIRA sales declined by 36.1% due to biosimilars. Management raised its fiscal year 2026 revenue forecast for SKYRIZI to $21.7 billion, but continued offsetting depends on maintaining momentum in psoriasis and inflammatory bowel diseases.
The neuroscience segment generated revenue exceeding $3.2 billion in Q2 fiscal year 2026, with operational growth of approximately 20%. Vraylar generated approximately $1.1 billion, with growth of approximately 19%, while Vialev sales reached approximately $256 million and grew by more than 27% compared with the previous quarter. Management expects neuroscience revenue of $12.7 billion in fiscal year 2026, including Vraylar sales approaching $4.1 billion and BOTOX Therapeutic sales approaching $4.2 billion.
Automated analysis for informational purposes only — not investment advice.
AbbVie announced on August 21, 2026, an objective response rate of 90% for ABBV-1480 with chemotherapy in squamous non-small cell lung cancer. The U.S. Food and Drug Administration also accepted for review on August 4, 2026, an application to expand the use of BOTOX Cosmetic for masseter muscle prominence in adults. Other catalysts include the review of subcutaneous SKYRIZI in Crohn's disease and RINVOQ applications in vitiligo and alopecia areata, with investigational products and uses remaining unapproved until regulatory decisions are issued.
AbbVie expects to complete the planned transaction in Q3 fiscal year 2026, adding long-acting assets in dermatological, respiratory, and inflammatory diseases. The company incorporated expected dilution of $0.14 into its fiscal year 2026 adjusted earnings per share guidance, more than offsetting the $0.10 improvement in the existing business. It also raised its forecast for adjusted research and development expenses to approximately $9.8 billion and net interest expense to approximately $2.9 billion, and targets a net debt-to-earnings ratio of two times within two to three years after the transaction closes.
The largest operational risk is concentration, as immunology generated approximately $8.8 billion out of roughly $17 billion in Q2 fiscal year 2026, including $5.5 billion from SKYRIZI. HUMIRA and IMBRUVICA also continue to decline by 36.1% and 29.4%, respectively, while aesthetics revenue fell 0.9%. The Apogee transaction adds financing costs and earnings dilution, while several assets, such as ABBV-1480, Temab-A, and ABBV-706, remain subject to development and regulatory approval risks.
